Meta-analysis shows chemoimmunotherapy enhances overall and progression-free survival in BTC patients, indicating its potential as a first-line approach.
Key Points
Chemoimmunotherapy significantly reduces the risk of death by 20% compared to chemotherapy alone.
The study included two randomized controlled trials with 1754 participants, enhancing the reliability of results.
Meta-analysis followed PRISMA 2020 guidelines and utilized robust sensitivity analyses to confirm findings.
This evidence supports incorporating chemoimmunotherapy as a standard treatment strategy in advanced biliary tract cancers.